FIELD: pharmaceuticals.
SUBSTANCE: present invention refers to a pharmaceutical composition containing 5 mg, 10 mg, 15 mg or 20 mg of suvorexant in amorphous form and a polymer which increases concentration of suvorexant, which is copovidone. Suvorexant pharmaceutical composition may additionally contain lactose, microcrystalline cellulose, sodium croscarmellose and magnesium stearate. Pharmaceutical composition is produced by extrusion of hot melt of mixture containing suvorexant and copovidone.
EFFECT: technical result consists in reducing the effect of food when the preparation suvorexant is introduced with food with high fat content.
5 cl, 5 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS OF SOLID DOSAGE FORMS OF OREXIN RECEPTOR ANTAGONIST | 2013 |
|
RU2759837C2 |
| POLYMER COMPOSITIONS OF CETP INHIBITORS | 2007 |
|
RU2457841C2 |
| COMPOSITION CONTAINING FENOFIBRIC ACID OR PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND CAPSULE CONTAINING COMPOSITION | 2008 |
|
RU2500398C2 |
| COMPOSITION OF THE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | 2014 |
|
RU2661399C1 |
| COMPOSITION CONTAINING PHENOFIBRIN ACID, ITS PHYSIOLOGICALLY ACCEPTABLE SALT OR DERIVATIVE | 2003 |
|
RU2356549C2 |
| METHOD FOR PREPARING SOLID DISPERSIONS OF HIGH CRYSTALLINE THERAPEUTIC COMPOUNDS | 2007 |
|
RU2454220C2 |
| METHOD FOR MELT GRANULATION | 2009 |
|
RU2491918C2 |
| PRO-MEDICATION COMPOSITION FOR STRUGGLE AGAINST HEPAPATITIS C VIRUS | 2006 |
|
RU2435592C2 |
| METHODS OF TREATING HEPATITIS C | 2013 |
|
RU2665365C2 |
| METHOD FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING UNSTABLE PLASTICISER | 2006 |
|
RU2430719C2 |
